These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22646305)

  • 1. Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity.
    Jeong YH; Bliden KP; Antonino MJ; Tantry US; Gurbel PA
    Platelets; 2013; 24(2):166-9. PubMed ID: 22646305
    [No Abstract]   [Full Text] [Related]  

  • 2. Prasugrel resistance: fact or fiction.
    Alexopoulos D
    Platelets; 2012; 23(2):83-90. PubMed ID: 21787175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
    Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
    Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
    Badr Eslam R; Lang IM; Kaider A; Panzer S
    Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.
    Storey RF; Bliden KP; Ecob R; Karunakaran A; Butler K; Wei C; Tantry U; Gurbel PA
    J Thromb Haemost; 2011 Sep; 9(9):1730-7. PubMed ID: 21707911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond platelet functional testing: value in the aggregate.
    Jakubowski JA
    Biomark Med; 2011 Feb; 5(1):5-8. PubMed ID: 21319961
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of milrinone on platelet activation as determined by TEG platelet mapping.
    Wesley MC; McGowan FX; Castro RA; Dissanayake S; Zurakowski D; Dinardo JA
    Anesth Analg; 2009 May; 108(5):1425-9. PubMed ID: 19372315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity.
    Alexopoulos D; Plakomyti TE; Xanthopoulou I
    Int J Cardiol; 2012 Feb; 154(3):333-4. PubMed ID: 22075413
    [No Abstract]   [Full Text] [Related]  

  • 12. Dexmedetomidine Does Not Affect Platelet Function Measured With TEG 6S and Platelet Mapping Assay in Whole Blood.
    Yoshikawa Y; Takahashi K; Edanaga M; Hirata N; Yamakage M
    J Cardiothorac Vasc Anesth; 2018 Dec; 32(6):e9-e11. PubMed ID: 30072264
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
    Kuijpers MJ; Megens RT; Nikookhesal E; Feijge MA; De Mey JG; oude Egbrink MG; van Giezen JJ; Heemskerk JW
    Thromb Haemost; 2011 Dec; 106(6):1179-88. PubMed ID: 22071958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target.
    Straub A; Krajewski S; Hohmann JD; Westein E; Jia F; Bassler N; Selan C; Kurz J; Wendel HP; Dezfouli S; Yuan Y; Nandurkar H; Jackson S; Hickey MJ; Peter K
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1607-16. PubMed ID: 21512161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
    Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets.
    Bambace NM; Levis JE; Holmes CE
    Platelets; 2010; 21(2):85-93. PubMed ID: 20063989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect?
    Sarode R
    Transfusion; 2012 Apr; 52(4):695-701; quiz 694. PubMed ID: 21854398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists.
    Thalji RK; Aiyar N; Davenport EA; Erhardt JA; Kallal LA; Morrow DM; Senadhi S; Burns-Kurtis CL; Marino JP
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4104-7. PubMed ID: 20542694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels.
    Voisin S; Bongard V; Tidjane MA; Lhermusier T; Carrié D; Sié P
    Thromb Haemost; 2011 Aug; 106(2):227-9. PubMed ID: 21544318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
    Frelinger AL; Jakubowski JA; Li Y; Barnard MR; Linden MD; Tarnow I; Fox ML; Sugidachi A; Winters KJ; Furman MI; Michelson AD
    J Thromb Haemost; 2008 Feb; 6(2):359-65. PubMed ID: 18021304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.